Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868096 | 0.82 | LTA4H (0.41) | ACHECHRM5CHRM1CHRM3SIGMAR1 | |
| SCHEMBL6215877 | 0.80 | ACHE (0.52) | KDM4EALDH1A1ACHECHRM5CHRM1 | |
| SCHEMBL13361340 | 0.80 | SMN1; SMN2 (0.60) | KDM4EALDH1A1CHRM5CHRM1SIGMAR1 | |
| SCHEMBL6369665 | 0.80 | ALDH1A1 (0.47) | ALDH1A1CHRM5CHRM1CHRM3SIGMAR1 | |
| SCHEMBL4832645 | 0.78 | CHRM2 (0.44) | ALDH1A1CHRM5CHRM1CHRM3SIGMAR1 | |
| SCHEMBL4832630 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1ACHECHRM5CHRM1 | |
| SCHEMBL4842101 | 0.78 | MEN1 (0.46) | ACHECHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL9095901 | 0.78 | CHRM1 (0.49) | ALDH1A1CHRM5CHRM1CHRM3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4841000 | 0.77 | KDM4E (0.49) | KDM4EALDH1A1ACHECHRM5CHRM1 | |
| SCHEMBL6983158 | 0.77 | CHRM1 (0.47) | CHRM5CHRM1CHRM3SIGMAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1289972-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | KDM4E 3205/4885ALDH1A1 2408/4885ACHE 3190/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | KDM4E 712/4885ALDH1A1 2527/4885ACHE 1271/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | KDM4E 3503/4885ALDH1A1 2261/4885ACHE 2174/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | KDM4E 3503/4885ALDH1A1 2261/4885ACHE 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.